Dovitinib Trial

Status: Start-Up Phase

An exploratory multinational Phase 1/2 trial, led by The Hospital for Sick Children (SickKids) and Children’s Cancer Institute, evaluating dovitinib in combination with standard of care.

  • Osteosarcoma

  • Seamless Phase ½ biomarker-driven enrollment.

  • Define safe dosing for dovitinib, both alone and in combination with chemotherapy, assess drug efficacy, and evaluate biomarkers.

  • ~40 children across multiple cancer types and centers around the world.

  • Daniel Morgenstern, MD, PhD

    Staff Physician, Haematology/Oncology at The Hospital for Sick Children (Sickkids)

    David Ziegler, MBBS, BSc (Med), MD/PhD, FRACP

    Group Leader, Clinical Research Fellow & Haematology/Oncology at Children’s Cancer Insti!u!e